Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
January 17, 2022 Cover
Volume 100, Issue 2
Our analysis of the key policies, market trends, and economic forces that will affect chemistry worldwide as the pandemic continues
Cover image:Our analysis of the key policies, market trends, and economic forces that will affect chemistry worldwide as the pandemic continues
Credit: C&EN/Shutterstock
C&EN’s World Chemical Outlook 2022
Our analysis of the key policies, market trends, and economic forces that will affect chemistry worldwide as the pandemic continues
New drug approvals held steady in 2021
The FDA maintained its pace for shepherding new molecular entities to market despite the ongoing pandemic
Respirator filter expert Simon Smith explains what’s in a mask and what drives personal protective equipment R&D
He spent 30 years working to address particulate and chemical hazards, including anticipating a pandemic such as COVID-19
-
Career Ladder: Erik Luber
This boundary-crossing scientist has expertise in physics, chemistry, and biology.
-
Drugmakers embrace AI through deals with specialist firms
Companies seek to accelerate discovery and improve drug candidate quality with high-speed computational models
-
US EPA turns down requests for more PFAS toxicity testing
Agency grants advocates’ petition but won’t require Chemours to study additional fluorochemicals
ADVERTISEMENT
Science Concentrates
Drugmakers embrace AI through deals with specialist firms
Companies seek to accelerate discovery and improve drug candidate quality with high-speed computational models
Business & Policy Concentrates
- Pfizer buys into next-generation gene editing in $300 million deal with Beam Therapeutics
- Optimvia to scale new route to synthetic heparin
- US EPA turns down requests for more PFAS toxicity testing
- New York bans televisions with organohalogen flame retardants
- Mercedes interior uses cactus and mushroom leather, biotech silk
